The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Open accessAbstract
BACKGROUND: , locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study. METHODS: -mutated non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy. The primary end point was objective response assessed by blinded independent central review. Secondary end points included the duration of response, progression-free survival, overall survival, and safety. RESULTS: -mutated NSCLC had been treated (median follow-up, 12.9 months); 98.3% had previously received both chemotherapy and immunotherapy. Of 112 patients with measurable disease at baseline, 48 (42.9%) had a confirmed objective response. The median duration of response was 8.5 months (95% confidence interval [CI], 6.2 to 13.8), and the median progression-free survival was 6.5 months (95% CI, 4.7 to 8.4). As of January 15, 2022 (median follow-up, 15.6 months), the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0 to 51.8). Treatment-related adverse events occurred in 97.4% of the patients - grade 1 or 2 in 52.6% and grade 3 or higher in 44.8% (including two grade 5 events) - and resulted in drug discontinuation in 6.9% of patients. CONCLUSIONS: -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results indicate the rapid development of acquired resistance to KRAS G12C inhibitors [18, 26, 27, 49].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from both CodeBreak 100 for sotorasib and KRYSTAL-1 for adagrasib led to the approval of these inhibitors to treat G12C-mutant NSCLC [51,53,94].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [94]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In clinical trials, the inactive-state KRASG12C mutant-specific inhibitors adagrasib (MRTX849) and sotorasib (AMG510) achieved 37–43% anti-tumor response rates in NSCLC patients with most experiencing disease progression 6–12 months after initiation of therapy7–9.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For adagrasib, an ORR was 23.0% in CRC, compared to 42.8% in NSCLC (Table 1) [27, 48].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Colorectal cancer, in particular, has a markedly lower response rate to KRAS G12C inhibitors compared to non-small cell lung cancer.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the therapeutic response to KRAS G12C inhibition was short-lived, with quick emergence of acquired resistance.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in NSCLC patients, the response to KRAS G12C inhibitors was often short-lived, with a DOR of 10.9–11.1 months and PFS of 6.3–6.8 months for sotorasib, and a DOR of 8.5 months and PFS of 6.5 months for adagrasib (Table 1).”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The overall response rate of inactive-state KRASG12C inhibitors sotorasib and adagrasib in patients with KRASG12C mutant NSCLC is 37-43%, a major advance albeit with significant room for improvement7,8.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“This is further supported by a numerically higher ORR seen with divarasib in patients with non-small cell lung cancer (56.4%) compared with sotorasib (37% in a phase 2 trial and 28% in a phase 3 trial) and adagrasib (43% in a phase 2 trial)11,23–25.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical studies have shown that many patients with KRAS G12C cancers did not respond to sotorasib and adagrasib.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Because KRAS mutations are often clonal founder events, mutant KRAS ctDNA can serve as a highly informative molecular marker for tumor burden, treatment response, minimal residual disease, and emergence of resistance [29,47,77,78].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective and irreversible oral small-molecule inhibitor of the mutant KRAS G12C protein18 and was recently approved by the FDA for treatment of NSCLC who have received at least 1 prior systemic therapy19.”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [19]
In the citing paper
“This subset of patients that were evaluable for longitudinal KRASG12C ctDNA response in Cohort A exhibited a slightly higher ORR (56.4%, 22/39 cycle ctDNA response evaluable) compared to Cohort A overall (50.5%, 48/95 RECIST 1.1 evaluable patients)19”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [19]
In the citing paper
“Updated data from 116 patients with previously treated NSCLC included in a registrational phase II cohort of KRYSTAL-1 showed an ORR of 42.9%, a DCR of 79.5%, median DoR of 8.5 months, median PFS of 6.5 months, median OS of 12.6 months and estimated 1-year OS of 50.8% with adagrasib83.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [83]
In the citing paper
“While these drugs clearly have clinical activity, overall response rates (30-40%) and disease control (~60%) in NSCLC are modest and transient, with median duration less than one year (9,10).”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [10]
In the citing paper
“Multiple mechanisms of intrinsic and acquired resistance (10,12,13), have been identified; hence, drug combinations will likely be needed to maximize the clinical efficacy of G12Cis (and probably other, emerging KRAS inhibitors) in NSCLC and other diseases.”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [10]
In the citing paper
“The phase II portion of KRYSTAL-2 included 116 patients with KRAS G12C NSCLC treated with adagrasib 600 mg bid [100]. All patients had prior platinum-doublet chemotherapy and 98.3% had received both chemotherapy and checkpoint inhibitor therapy. With a median follow-up of 12.9 months, the ORR was 42.9%.”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [100]
In the citing paper
“Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0–51.8) [100].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationGaron, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Self-citationAllele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Self-citationRapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543
Mehta, M. P., Rodrigus, P. T. R., Terhaard, C. H. J., Rao, A. R., Suh, J. H., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M. H., Komaki, R. U., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.122 · Cited by 466
Targeting the untargetable KRAS in cancer therapy
Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366
Flagged first, then by citations
Research works printed but not linked: 1
- Mirati Therapeutics. U.S. Food and Drug Administration (FDA) accepts Mirati Therapeutics’ new drug application for adagrasib as treatment of previously treated KRASG12C-mutated non-small cell lung cancer. February 15 2022 (https://ir.mirati.com/press-releases/press-release-details/2022/U.S.-Food-and-Drug-Administration-FDA-Accepts-Mirati-Therapeutics-New-Drug-Application-for-Adagrasib-as-Treatment-of-Previously-Treated-KRASG12C-Mutated-Non-Small-Cell-Lung-Cancer/default.aspx).
Cited by
Sorted by citations
Items 501–600 of 1,002
Satti, P., Chinnakadoori, S. R., Bharath, P., & Ramachandran, D. (2025) · Separation Science Plus · doi:10.1002/sscp.70024 · Cited by 5
Conrad, R. J., Mondo, J. A., Wang, L., Liu, P. S., Lai, Z., Choudhury, F. K., Li, Q., Wong, W. R., Lee, J., Shanahan, F., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00463-z · Cited by 5
Cantor, D. J., Nimeiri, H. S., Horn, L., West, M., Ben‐Shachar, R., Huerga, I., Patel, J. D., & Aggarwal, C. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.05.007 · Cited by 5
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia
Bravo, G. M., Loghavi, S., Li, Z., Chien, K. S., Kanagal‐Shamanna, R., Bataller, Á., Natu, A., Gurney, M. E., Bazinet, A., Hammond, D. E., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016529 · Cited by 5
Generation of actionable, cancer-specific neoantigens from KRAS(G12C) with adagrasib
Maso, L., Rajak, E., Hattori, T., Hu, Z., Koide, A., Neel, B. G., & Koide, S. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2509012122 · Cited by 5
Li, H., Liu, C., & Wang, Y. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14882 · Cited by 5
Hong, S., Jeon, M., Kwon, J., Park, H., Lee, G., Kim, K., & Ahn, S. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45070371 · Cited by 5
Targeting KRAS -Mutated NSCLC: Novel TKIs and Beyond
Cantor, D. J., & Aggarwal, C. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1658 · Cited by 5
Pan, L., Shen, W., Tang, H., You, L., Chen, G., Tang, Y., & Lu, W. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s437293 · Cited by 5
Liu, X., Zhang, Y., & He, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27591 · Cited by 5
Larsen, E. K., Blanco, M. A., Rabara, D., & Stephen, A. G. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3822-4_12 · Cited by 5
Unconventional strategy could be the future: From target to KRAS broad range treatment
Fancelli, S., Petroni, G., Pillozzi, S., & Antonuzzo, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29739 · Cited by 6
KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
Xiao, A., & Fakih, M. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.05.004 · Cited by 5
Ugai, S., Yao, Q., Takashima, Y., Zhong, Y., Matsuda, K., Kawamura, H., Imamura, Y., Okadome, K., Mima, K., Arima, K., et al. (2024) · Cancer Science · doi:10.1111/cas.16262 · Cited by 6
Shatara, M., Schieffer, K. M., Melas, M., Varga, E. A., Thomas, D., Bucknor, B. A., Costello, H. M., Wheeler, G., Kelly, B., Miller, K. E., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1453309 · Cited by 5
Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer
Dekker, S. E., & Deng, L. (2024) · Cancers · doi:10.3390/cancers16223885 · Cited by 5
The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma
Ma, S., Li, K., Wang, R.-R., Qian, J., Fan, Y., Qin, X., Li, M., & Wu, L. (2024) · Clinical Surgical Oncology · doi:10.1016/j.cson.2024.100069 · Cited by 6
Role of silent mutations in KRAS-mutant tumors
Lu, J. G., Zhou, C., Pan, F., Liu, H., Jiang, H., Zhong, H., & Han, B. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003405 · Cited by 6
KRAS Oncoprotein Signaling in Cancer
Lito, P. (2025) · New England Journal of Medicine · doi:10.1056/nejmcibr2408099 · Cited by 6
Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients
Yin, X., Shen, H., Wang, H., Wang, Q., Zhang, S., Zhang, C., Jia, Q., Guo, S., Xu, X., Zhang, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57520-3 · Cited by 5
Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
Cherri, S., Melocchi, L., Gandolfi, L., Rossi, G., & Zaniboni, A. (2023) · Life · doi:10.3390/life13020395 · Cited by 5
Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the MousePreprint
Vaishnavi, A., Kinsey, C. G., & McMahon, M. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041385 · Cited by 5
García-Román, S., Garzón‐Ibáñez, M., Bertrán-Alamillo, J., Jordana‐Ariza, N., Giménez-Capitán, A. A., García‐Peláez, B., Vives-Usano, M., Codony‐Servat, J., d'Hondt, E., Rosell, R., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101878 · Cited by 4
M-Ras distinct activation scenarios: A mechanistic outlook and targeting
Xu, L., Liu, Y., Jang, H., & Nussinov, R. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.11.025 · Cited by 4
Targeted Therapies in Non–Small Cell Lung Cancer: A Contemporary Review
Abdelmonem, A., Bikram Shah, B., Shebli, M. A., & Tabbara, I. A. (2026) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001275 · Cited by 4
Wang, W., Zhang, S., Wang, Y., Ge, J., & Li, L. (2025) · Water Research · doi:10.1016/j.watres.2025.125285 · Cited by 4
Mutukuru, M., Kandula, S. R., Ramakrishna, V., Sanka, P., Sidde, G. P., Muzzamil, S. M., Uppara, H. B., & Prasad, P. D. (2026) · International Journal of Cancer · doi:10.1002/ijc.70318 · Cited by 4
Yu, J., Zhu, M., Zhu, Y., & Shu, Q. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004704 · Cited by 4
Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches
Kidwai, N., Chen, M. F., Postow, M. A., Hassel, J. C., & Callahan, M. K. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432462 · Cited by 5
Discovery of RMC-6291, a potent, orally bioavailable, covalent RAS(ON) G12C selective inhibitor
Cregg, J., Pota, K., Gill, A. L., & Koltun, E. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00006-1 · Cited by 4
An overview of PROTACs targeting KRAS and SOS1 as antitumor agents
Han, Z., Wu, Q., Rao, H., Xu, T., & Zhou, C. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130283 · Cited by 5
Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer
Jayachandran, P., Elliott, A., Soni, S., Battaglin, F., Mittal, P., Algaze, S. D., Lo, J. H., Yang, Y., Ashouri, K., Torres, E. T. R., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03484-z · Cited by 6
Lu, H. J., Fu, W., Xia, Y., Yan, Y., Shu, C.-H., Chen, Y., Xu, C., Zheng, P., Shen, X., Cui, R., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02657-9 · Cited by 4
Huang, Y., Zhu, T., Zhong, J., & Yuan, J. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00253 · Cited by 4
Jung, O., Soto, A., Wolfe, A. L., & Mahajan, S. S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329946 · Cited by 4
Mitamura, A., Tsujinaka, S., Fujishima, F., Sawada, K., Hikage, M., Miura, T., Kitamura, Y., Hatsuzawa, Y., Nakano, T., & Shibata, C. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i8.109088 · Cited by 9
Wooster, M. E., May, M. S., Agrawal, P., Lee, J., May, B. L., Ma, X., Bogdan, S., Shu, C. A., Henick, B. S., Saqi, A., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf236 · Cited by 4
Self-citationMechanisms and current advances in treating KRAS-mutated lung cancer
Chao, C. H.-Y., & Di, Y. P. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.08.001 · Cited by 6
p53: An Immune Ecosystem Manipulator
Nian, Z., Dou, Y., & Wei, H. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3628 · Cited by 4
Ali, N., Alotaibi, F. T., Babu, M. A., Singh, T., Alaseem, A. M., Tyagi, Y., & Bansal, N. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70190 · Cited by 6
Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12C
Landry, M. L., Malhotra, S., Beresini, M. H., Chan, C. C. C., Chan, E., de la Cruz, C. C., Endres, N., Evangelista, M., Gustafson, A. E., Hu, D. X., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02279 · Cited by 4
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer
Alonso, S., Chu, K., Granowsky, E., Saraiba-Rabanales, V., Parsons, M. J., Gunasinghe, H. I., Shia, J., Yaeger, R., & Dow, L. E. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.04.009 · Cited by 8
Moore, A. R., Biehs, B., Kljavin, N. M., Nguyen, T. T. T., Shah, A. M., Burton, J., Jiang, H., Tan, J., Chakroborty, D., Wang, L., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02611-0 · Cited by 5
Mahadevan, K. K., Maldonado, A. S., Li, B., Bickert, A. A., Perdyan, A., Kumbhar, S. V., Piya, S., Sockwell, A. M., Morse, S. J., Arian, K. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75960-3 · Cited by 12
Shu, C., & Liu, Y. (2022) · Cancer Management and Research · doi:10.2147/cmar.s387665 · Cited by 4
Brooun, A., Zhang, J., Li, C., Lam, R., Cheng, H., Shoemaker, R. F., Daly, J., & Olaharski, A. J. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116601 · Cited by 4
Self-citationA Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer
Kulkarni, P., Mohanty, A. R., Ramisetty, S. K., Duvivier, H. L., Khan, A., Shrestha, S., Tan, T., Merla, A., El-Hajjaoui, M., Malhotra, J. D., et al. (2023) · Biomolecules · doi:10.3390/biom13111587 · Cited by 4
All Roads Lead to Rome: YAP/TAZ Activity Influences Efficacy of KRASG12C Inhibitors
Johnson, C. W., & Haigis, K. M. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-3547 · Cited by 4
Kim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2024) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2023.11.01 · Cited by 5
The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype
Fojo, T., LaRose, M., & Bates, S. E. (2024) · The Oncologist · doi:10.1093/oncolo/oyae042 · Cited by 4
Prakash, S., Tyagi, P., Singh, P., Rajkumar, R., & Singh, A. P. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096331827240911165227 · Cited by 8
The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer
Zhao, X., Zheng, Y., Wang, Y., Zhang, M., Dong, Z., Liu, Y., & Sun, M. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s484209 · Cited by 4
The RAS Signaling Network and Cancer
Hibshman, P. S., & Der, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_17 · Cited by 4
Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC
Shiller, M., Johnson, M. L., Auber, R., & Patel, S. P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1459737 · Cited by 8
Self-citationAnalysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations
Ghazali, N., Feng, J., Hueniken, K., Khan, K., Balaratnam, K., Waddell, T. K., Yasufuku, K., Pierre, A. F., Donahoe, L. L., Wakeam, E., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241308466 · Cited by 4
Harnessing the FBXW7 Somatic Mutant R465C for Targeted Protein Degradation
Basu, A. A., Zhang, C., Rouhimoghadam, M., Vasudevan, A., Reitsma, J. M., & Zhang, X. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c17331 · Cited by 4
Beyond First-Generation KRAS Inhibitors: BBO-8520 Tests the Dual Mechanism Hypothesis
Zhou, Z., & Westover, K. D. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1885 · Cited by 4
Shah, P. A., Wiman, K. G., Cichowski, K. M., & Rodon, J. A. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473616 · Cited by 4
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity
Freed-Pastor, W. A., & Aguirre, A. J. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.018 · Cited by 4
Zhang, Y., Zeng, F., Peng, S., Chen, Y., Jiang, W., Wang, Z., Li, D., Huang, Z., Qin, H., Yan, H., et al. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2265810 · Cited by 4
TO MARKET, TO MARKET–2022: SMALL MOLECULES
Araujo, E., Bell, I. M., Burckle, A. J., Koester, D. C., Manning, J. R., Castanedo, G. M., Zeng, M., Dhar, T. G. M., Holmberg‐Douglas, N., Welin, E. R., et al. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch24 · Cited by 4
Chao, T., Wang, Z., Bowne, W. B., Yudkoff, C. J., Torjani, A., Swaminathan, V., Kavanagh, T. R., Roadarmel, A., Sholevar, C. J., Cannaday, S., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0005-oa · Cited by 4
KRAS degradation averts PDAC chemoresistance
Leonhardt, L., & Hebrok, M. (2024) · Nature Cancer · doi:10.1038/s43018-023-00708-7 · Cited by 4
Baltanás, F. C., Kramer‐Drauberg, M., García‐Navas, R., Patrucco, E., Petrini, E., Arnhof, H., Juan, A. O.-S., Rodríguez-Ramos, P., Borrajo, J., Calzada, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.18.613686 · Cited by 4
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRCPreprint
Alonso, S., Chu, K., Parsons, M. J., Granowsky, E., Gunasinghe, H. I., Shia, J., Yaeger, R. D., & Dow, L. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.05.668666 · Cited by 4
Faber, E. B., Baca, Y., Xiu, J., Walker, P., Manji, G. A., Gholami, S., Saeed, A., Prakash, A., Botta, G. P., Sohal, D. P. S., et al. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100042 · Cited by 3
Podder, V., Bellur, S. S., Margolin, K. A., Advani, P. P., Mahtani, R. L., Subbiah, V., Novo, G. B., Ranjan, T., & Ahluwalia, M. S. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01593-8 · Cited by 4
Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer
Vlachavas, E., Voutetakis, K., Kosmidou, V., Tsikalakis, S., Roditis, S., Pateas, K., Kim, R., Pagel, K. A., Wolf, S., Warsow, G., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.13814 · Cited by 3
Schram, A. M., Boni, V., Adjei, A. A., Olszanski, A. J., Vieito, M., Francis, J. H., Kurman, M. R., Ahsan, J. M., Tomkinson, B., & Garralda, E. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104300 · Cited by 3
Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Roy, J., Mouawad, R., Kyani, A., Hanafi, M., Xu, Y., Wen, B., Sun, D., & Neamati, N. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03159 · Cited by 3
Cui, R., Wang, G., Hu, R.-H., Wang, Y., Mu, H., Song, Y., Chen, B., & Jiang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1568976 · Cited by 3
Analysis of Pan-Specific Inhibitors of Oncogenic Mutant Forms of KRAS GTPase
Eliseev, I. A., Shkil, D. O., Shumakova, V. S., Chernyshov, V. V., Balakin, K. V., & Ivanov, R. A. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673372217250515031136 · Cited by 3
EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers
Han, J., Yu, B., Jing, J., He, X., Hua, Y., & Xu, G. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01075-4 · Cited by 3
Pan-Cancer Analyses Reveal Disparities in Tumor Genomic Profiles by Race/Ethnicity, Age, and Sex
Wen, W., Choi, J. Y., Singh, B., Li, L., Toriola, A. T., Ciombor, K. K., Park, B. H., Shu, X., Idrees, K., Zheng, W., et al. (2025) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-25-0345 · Cited by 4
Oscanoa, J., Ross‐Adams, H., Ullah, A. Z. M. D., Kolvekar, T. S., Sivapalan, L., Gadaleta, E., Thorn, G. J., Abdollahyan, M., Imrali, A., Saad, A. B., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102550 · Cited by 3
Tirpe, A., Nutu, A. M., Busuioc, C. I., Pop, O. L., & Berindan‐Neagoe, I. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1677471 · Cited by 5
Zheng, Y., Su, C., Pan, J., Wang, Y., Zhao, M., Zhang, M., Yan, P., Liu, N., & Sun, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1663502 · Cited by 4
Yu, A., He, J., Meng, L., Shi, Z., Chan, E. W., Jian, J., Merchant, M. A., Kaur, S., & Xu, K. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c02696 · Cited by 3
Advances on drug therapy for KRAS-mutant non-small-cell lung cancer
Tian, T., & Li, W. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102668 · Cited by 4
Wu, S.-G., & Chao-Chi, H. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.02.009 · Cited by 3
Olmo-González, D., Zhou, M., Oliveira, N. G., Zhou, F., Yan, F., González, J., València-Clua, K., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Giménez-Capitán, A. A., et al. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-02998-z · Cited by 3
Systematic and precise interventions for KRAS-mutant cancers
Liang, J., Wu, J., Zhang, Y., Wang, H., Zheng, Y., & He, Q. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00763-7 · Cited by 4
Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations
Deng, J., Shen, S., Huang, L., Xu, F., Huang, W., Huang, C., Zhang, Z., Liu, T., Tan, Y., & Li, Z. (2026) · Nature Communications · doi:10.1038/s41467-026-71093-9 · Cited by 4
Janne, P. A., Johnson, M. L., Li, J., Pant, S., Dünzinger, U., Ilia, L., Möldner, K., Soh, J. E., & Yamamoto, N. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3725 · Cited by 3
Self-citationScheidegger, N. K., Schneider, C., Alexe, G., Wang, Y.-C., Alonzo, T. A., Basanthakumar, A. T., Bourgeois, W., Dudkiewicz-Garbicz, J., Khalid, D., Merickel, L. A., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025016208 · Cited by 4
Dragnev, K. H., Lubet, R. A., Miller, M. S., Sei, S., Fox, J. T., & You, M. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-23-0027 · Cited by 3
Rekowska, A. K., Rola, P., Kwiatkowska, A., Wójcik-Superczyńska, M., Gil, M., Krawczyk, P. A., & Milanowski, J. (2024) · Biomedicines · doi:10.3390/biomedicines12020325 · Cited by 3
Mesonephric adenocarcinoma of the uterine cervix with a prominent spindle cell component
Fan, Y., He, Y., Sun, L., Liu, T., & Shen, Y. (2024) · Oncology Letters · doi:10.3892/ol.2024.14641 · Cited by 3
Cregg, J., Edwards, A. V., Tomlinson, A. C. A., Gill, A. L., & Koltun, E. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00011-5 · Cited by 3
D'Alessio‐Sands, L., Gaynier, J., Michel‐Milian, V., Agbowuro, A. A., & Brackett, C. M. (2025) · Drug Development Research · doi:10.1002/ddr.70042 · Cited by 5
Kato, R., Solanki, H. S., Özakıncı, H., Desai, B., Gundlapalli, H., Yang, Y. C., Aronchik, I., Singh, M., Johnson, J., Marusyk, A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3714 · Cited by 3
Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma
Zou, J. P., Han, W., Hu, Y. T., Zeng, C., Li, J., Lei, W., Cao, J., Fei, Q., Shao, M., Yi, J., et al. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03680-x · Cited by 4
Current status of cancer genome medicine for pancreatic ductal adenocarcinoma
Doi, T., Ishikawa, T., Moriguchi, M., & Itoh, Y. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf012 · Cited by 3
Pan, Z., Qian, Y., Wang, Y., Zhang, T.-S., Song, X., Ding, H., Li, R., Zhang, Y., Wang, Z., Wang, H., et al. (2025) · Cancer Science · doi:10.1111/cas.70017 · Cited by 3
Primary urethral adenocarcinoma harbors recurrent KRAS and EGFR alterations
Zhao, T., Iafrate, A. J., & Wu, C. (2025) · Human Pathology · doi:10.1016/j.humpath.2025.105771 · Cited by 3
Wislez, M., Giannopoulou, A., Borget, I., Lindsay, C. R., Rothschild, S. I., Vincent, B., Milce, J., Sultan, I., Stollenwerk, B., & Pless, M. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2535225 · Cited by 3
New therapies for brain metastases: an update
Porte, M., & Massard, C. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001195 · Cited by 4
Wang, W., Alley, A., Sun, N., Tadesse, M., Wang, X., & Zhang, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1663766 · Cited by 3
Targeting K-Ras Mutations Show Promise Towards Ending Ras’s “Undruggable” Era
Adams, P. D., & Muhoza, D. (2022) · Protein and Peptide Letters · doi:10.2174/0929866529666221003124202 · Cited by 3
Targeted Therapy for Non–Small Cell Lung Cancer
Brea, E. J., & Rotow, J. K. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.009 · Cited by 4
Metadata
- Authors
- Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., Bazhenova, L., Negrao, M. V., Pennell, N. A., Zhang, J., Anderes, K., Der-Torossian, H., Kheoh, T., Velastegui, K., Yan, X., Christensen, J. G., Chao, R. C., & Spira, A. I.
- Affiliations
- From the Lowe Center for Thoracic Oncology, Dana–Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) — both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) — all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) — all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at...
- Roswell Park Comprehensive Cancer Center (US)
- ORCID
- Riely, Gregory J.
- Gadgeel, Shirish M.
- Heist, Rebecca S.
- Ou, Sai-Hong I.
- Johnson, Melissa L.
- Sabari, Joshua K.
- Leventakos, Konstantinos
- Yau, Edwin
- Bazhenova, Lyudmila
- Negrao, Marcelo V.
- Pennell, Nathan A.
- Zhang, Jun
- Anderes, Kenna
- Kheoh, Thian
- Velastegui, Karen
- Christensen, James G.
- Chao, Richard C.
- Spira, Alexander I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-14
- Volume
- 387
- Issue
- 2
- Pages
- 120-131
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281650778
- Cited by
- 1,061
- References
- 27
- Citations by year
- 2026: 247 · 2025: 270 · 2024: 285 · 2023: 203 · 2022: 56
- FWCI
- 131.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mirati Therapeutics, Inc.
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- adagrasib, KRAS G12C mutation, non-small cell lung cancer, KRAS inhibitors, objective response rate, progression-free survival, overall survival, central nervous system metastasis, treatment-related adverse events, previously treated patients
- MeSH terms
- Acetonitriles, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Piperazines, Pyrimidines, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
